Table 2.
PEGylated Drugs in Active Clinical Trials
| Name | Company | Phase | PEGylated Molecule | Indication(s) | PEG# |
|---|---|---|---|---|---|
| BAY94-9027 | Bayer | 3 | protein | Hemophilia A | 60 kDa, branched |
| Bax855 | Baxalta | 3** | protein | Hemophilia A | 2×20 kDa |
| Peglispro | Eli Lilly | 3 | protein | Type 1 and 2 Diabetes | 20 kDa |
| N8-GP | Novo Nordisk | 3 | protein | Hemophilia A | 40 kDa, branched |
| N80-GP | Novo Nordisk | 3 | protein | Hemophilia B | 40 kDa, branched |
| ADI PEG-20 | Polaris Group | 3 | enzyme | Cancer | 20 kDa |
| Revolixys kit (pegnivacogin) | Regado biosciences | 3◆ | aptamer | Percutaneous coronary intervention | 40 kDa, branched |
| NKTR-181 | Nektar | 3 | small molecule, oral | Chronic pain | <1 kDa |
| Fovista | Ophthotech/Nektar | 2 | aptamer | Wet age-related macular degeneration | 40 kDa, branched |
| NOX-A12 | NOXXON Pharma | 2 | aptamer | Multiple myeloma and chronic lympocytic leukemia | 40 kDa, branched |
| NOX-E36 | NOXXON Pharma | 2 | aptamer | Diabetic nephropathy | 40 kDa, branched |
| NOX-H94 | NOXXON Pharma | 2 | aptamer | Erythropoiesis-stimulating agent-hyporesponsive anemia | 40 kDa, branched |
| Zimura, ARC1905 | Ophthotech | 2 | aptamer | Age-related macular degeneration | 40 kDa |
| PEGPH20 | Halozyme | 2 | enzyme | Pancreatic cancer, orphan drug | 20 kDa |
| pegvaliase | BioMarin | 2 | enzyme | Phenylketonuria | 20 kDa |
| BMS-986036 | Bristol-Myers Squibb/Ambrx | 2 | proteins | Type 2 diabetes, NASH | 30 kDa |
| Peg adrenomedullin | Bayer | 1 | peptide | Lung Disease | 40 kDa |
| NKTR-102 | Nektar | 1-3 | small molecule | Many cancer indications | 20 kDa, 4-arm |
| NKTR-171 | Nektar | 1 | small molecule | Neuropathic pain | <1 kDa |
| PEG-SN-38 | Prolynx | 1 | small molecule | Solid tumors | 40 kDa, 4-arm |
#
PEG is linear unless otherwise noted
**
Biologics License Agreement filed in US
◆
Clinical Hold